Las Vegas, NV -- (SBWIRE) -- 10/10/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Cereplast Inc (OTCMKTS: CERP), NewLead Holdings Ltd (NASDAQ:NEWL), Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN), CytRx Corporation (NASDAQ:CYTR)
Cereplast Inc (OTCMKTS: CERP) managed to keep its fall at -11.73% on below -normal volume of 8.82M shares. The stock settled at $0.0143 after floating in a range of $0.01 to $0.02. Its latest price has reached market capitalization of $10.30 million. Its 52-week range has been $0.01 to $0.29. Cereplast, Inc. develops and commercializes bio-based resins. It provides Cereplast Compostables resins, which are compostable, bio-based, and ecologically sound substitutes for petroleum-based plastics targeting compostable bags, single-use food service products, and packaging applications.
Has CERP Found The Bottom and Ready To Move Up? Find Out Here
NewLead Holdings Ltd (NASDAQ:NEWL) traded down on a volume of 7.41 million, lower than its standard daily volume. Shares have dropped-0.49% to $0.102. Over the last twelve months, the stock has lost-81.51% and faced a worst price of $0.07. NewLead Holdings Ltd., a shipping and commodity company, is engaged in the transportation of refined products and dry bulk goods worldwide.
Has NEWL Found The Bottom And Ready To Gain Momentum? Find Out Here
Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) settled -11.13% lower at $2.43 on above-normal volume of 6.08M shares during the last trading day. The stock has its 12-month high at $11.36 and 52-week low price was $2.40. It traded in a range of $2.40 to $2.74 during the last trading day. Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally.
Will ACHN Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, CytRx Corporation (NASDAQ:CYTR) was down on high volume, trading at a volume of 4.81M versus its average daily volume of 266,701.00 shares. At $2.23, the stock has attained market capitalization of 67.99 million. CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs, aldoxorubicin and tamibarotene, which are in clinical development for cancer indications.
Why Should Investors Buy CYTR After the Recent Fall? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)